Tg Therapeutics (TGTX) Other Operating Expenses (2011 - 2026)

Tg Therapeutics' Other Operating Expenses history runs 16 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 146.99% year-over-year to $38.4 million in Q1 2026; TTM through Mar 2026 was $128.9 million, a 149.09% increase from a year earlier, with the FY2025 full-year figure at $100.7 million, up 102.86% from the prior year.
• Other Operating Expenses climbed to $38.4 million in Q1 2026 per TGTX's latest filing, from $38.1 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $38.4 million in Q1 2026 and bottomed at $2000.0 in Q3 2022.
• The 5-year median for Other Operating Expenses is $8.3 million (2024), against an average of $12.7 million.
• Across the five-year window, Other Operating Expenses plunged 99.96% in 2022 and surged 321100.0% in 2023, its largest moves.
• Year by year, Other Operating Expenses stood at $13.2 million in 2022, then slumped by 40.62% to $7.9 million in 2023, then soared by 136.3% to $18.6 million in 2024, then jumped by 105.52% to $38.1 million in 2025, then climbed by 0.64% to $38.4 million in 2026.
• Per Business Quant, the three latest TGTX Other Operating Expenses figures stand at $38.4 million (Q1 2026), $38.1 million (Q4 2025), and $33.4 million (Q3 2025).